Literature DB >> 25147602

Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists.

Stefan Schunk1, Klaus Linz1, Sven Frormann1, Claudia Hinze1, Stefan Oberbörsch1, Bernd Sundermann1, Saskia Zemolka1, Werner Englberger1, Tieno Germann1, Thomas Christoph1, Babette-Y Kögel1, Wolfgang Schröder1, Stephanie Harlfinger1, Derek Saunders1, Achim Kless1, Hans Schick2, Helmut Sonnenschein2.   

Abstract

We report the discovery of spiro[cyclohexane-pyrano[3,4-b]indole]-amines, as functional nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonists with strong efficacy in preclinical models of acute and neuropathic pain. Utilizing 4-(dimethylamino)-4-phenylcyclo-hexanone 1 and tryptophol in an oxa-Pictet-Spengler reaction led to the formation of spiroether 2, representing a novel NOP and opioid peptide receptor agonistic chemotype. This finding initially stems from the systematic derivatization of 1, which resulted in alcohols 3-5, ethers 6 and 7, amines 8-10, 22-24, and 26-28, amides 11 and 25, and urea 12, many with low nanomolar binding affinities at the NOP and mu opioid peptide (MOP) receptors.

Entities:  

Keywords:  MOP receptor agonist; NOP receptor agonist

Year:  2014        PMID: 25147602      PMCID: PMC4137372          DOI: 10.1021/ml500116x

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

1.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

2.  Photocell measurements of rat motor activity. A contribution to sensitivity and variation in behavioral observations.

Authors:  E Ericson; J Samuelsson; S Ahlenius
Journal:  J Pharmacol Methods       Date:  1991-04

3.  A preclinical comparison between different opioids: antinociceptive versus adverse effects.

Authors:  Theo F Meert; Hilde A Vermeirsch
Journal:  Pharmacol Biochem Behav       Date:  2005-01-07       Impact factor: 3.533

Review 4.  The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders.

Authors:  Lawrence Toll
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.

Authors:  Colette M Cremeans; Erin Gruley; Donald J Kyle; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

6.  4-aryl-4-aminocyclohexanones and their derivatives, a novel class of analgesics. 3. m-Hydroxyphenyl derivates.

Authors:  D Lednicer; P F Von Voigtlander; D E Emmert
Journal:  J Med Chem       Date:  1981-03       Impact factor: 7.446

7.  (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Kögel; Klaus Schiene; Hagen-Heinrich Hennies; Werner Englberger; Michael Haurand; Ulrich Jahnel; Thomas I F H Cremers; Elmar Friderichs; Jean De Vry
Journal:  J Pharmacol Exp Ther       Date:  2007-07-26       Impact factor: 4.030

8.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.

Authors:  J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

9.  Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Authors:  R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

10.  Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.

Authors:  Aaron A Thompson; Wei Liu; Eugene Chun; Vsevolod Katritch; Huixian Wu; Eyal Vardy; Xi-Ping Huang; Claudio Trapella; Remo Guerrini; Girolamo Calo; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

View more
  6 in total

1.  Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.

Authors:  Stefan Schunk; Klaus Linz; Claudia Hinze; Sven Frormann; Stefan Oberbörsch; Bernd Sundermann; Saskia Zemolka; Werner Englberger; Tieno Germann; Thomas Christoph; Babette-Y Kögel; Wolfgang Schröder; Stephanie Harlfinger; Derek Saunders; Achim Kless; Hans Schick; Helmut Sonnenschein
Journal:  ACS Med Chem Lett       Date:  2014-06-24       Impact factor: 4.345

Review 2.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

3.  Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.

Authors:  G Calo; D G Lambert
Journal:  Br J Anaesth       Date:  2018-08-22       Impact factor: 9.166

4.  A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism.

Authors:  Anna Fantinati; Sara Bianco; Remo Guerrini; Severo Salvadori; Salvatore Pacifico; Maria Camilla Cerlesi; Girolamo Calo; Claudio Trapella
Journal:  Sci Rep       Date:  2017-05-25       Impact factor: 4.379

5.  Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist.

Authors:  Anna Rizzi; Maria Camilla Cerlesi; Chiara Ruzza; Davide Malfacini; Federica Ferrari; Sara Bianco; Tommaso Costa; Remo Guerrini; Claudio Trapella; Girolamo Calo'
Journal:  Pharmacol Res Perspect       Date:  2016-08-02

6.  Synthesis of Indofulvin Pseudo-Natural Products Yields a New Autophagy Inhibitor Chemotype.

Authors:  Annina Burhop; Sukdev Bag; Michael Grigalunas; Sophie Woitalla; Pia Bodenbinder; Lukas Brieger; Carsten Strohmann; Axel Pahl; Sonja Sievers; Herbert Waldmann
Journal:  Adv Sci (Weinh)       Date:  2021-08-04       Impact factor: 16.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.